Coherus BioSciences, Inc. announced a clinical collaboration with STORM Therapeutics Ltd. to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor. This collaboration will involve a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.
The Phase 2 portion of the study is designed to evaluate expansion cohorts in these indications, enrolling up to 188 patients in the United States. Under the terms of the clinical trial collaboration and supply agreement, Coherus will provide LOQTORZI, while STORM will serve as the sponsor of the clinical combination trial.
Both companies will retain all commercial rights to their respective compounds, whether as monotherapies or combination therapies. This collaboration represents a strategic effort to expand LOQTORZI's potential indications and enhance outcomes for patients with various solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.